474 related articles for article (PubMed ID: 21415162)
41. Biomarkers for Major Depressive Disorder: Economic Considerations.
Bogavac-Stanojevic N; Lakic D
Drug Dev Res; 2016 Nov; 77(7):374-378. PubMed ID: 27546547
[TBL] [Abstract][Full Text] [Related]
42. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
McLaughlin TP; Eaddy MT; Grudzinski AN
Clin Ther; 2004 Jan; 26(1):115-24. PubMed ID: 14996524
[TBL] [Abstract][Full Text] [Related]
43. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
[TBL] [Abstract][Full Text] [Related]
44. Escitalopram: a review of its use in the management of major depressive disorder in adults.
Garnock-Jones KP; McCormack PL
CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
[TBL] [Abstract][Full Text] [Related]
45. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
[TBL] [Abstract][Full Text] [Related]
46. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database.
Eaddy MT; Druss BG; Sarnes MW; Regan TS; Frankum LE
J Manag Care Pharm; 2005 Mar; 11(2):145-50. PubMed ID: 15766321
[TBL] [Abstract][Full Text] [Related]
47. Economic Outcomes of First-Line Regimen Switching Among Stable Patients with HIV.
Rosenblatt L; Buikema AR; Seare J; Bengtson LGS; Johnson J; Cao F; Villasis-Keever A
J Manag Care Spec Pharm; 2017 Jul; 23(7):725-734. PubMed ID: 28650246
[TBL] [Abstract][Full Text] [Related]
48. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
49. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
50. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
[TBL] [Abstract][Full Text] [Related]
51. A population-based study of the use of selective serotonin reuptake inhibitors before and after introduction of generic equivalents.
Bolton JM; Dahl M; Sareen J; Enns MW; Leslie WD; Collins DM; Alessi-Severini S
Can J Psychiatry; 2012 Apr; 57(4):223-9. PubMed ID: 22480587
[TBL] [Abstract][Full Text] [Related]
52. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.
Raskin J; George T; Granger RE; Hussain N; Zhao GW; Marangell LB
J Psychiatr Res; 2012 May; 46(5):667-74. PubMed ID: 22410206
[TBL] [Abstract][Full Text] [Related]
53. Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.
Yin J; Song X; Wang C; Lin X; Miao M
BMC Psychiatry; 2023 Nov; 23(1):876. PubMed ID: 38001423
[TBL] [Abstract][Full Text] [Related]
54. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
55. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Armstrong EP; Skrepnek GH; Haim Erder M
Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
[TBL] [Abstract][Full Text] [Related]
56. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
57. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
Hamer AM; Hartung DM; Haxby DG; Ketchum KL; Pollack DA
J Manag Care Pharm; 2006; 12(6):449-56. PubMed ID: 16925452
[TBL] [Abstract][Full Text] [Related]
58. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.
Papakostas GI; Cooper-Kazaz R; Appelhof BC; Posternak MA; Johnson DP; Klibanski A; Lerer B; Fava M
Int Clin Psychopharmacol; 2009 Jan; 24(1):19-25. PubMed ID: 19092448
[TBL] [Abstract][Full Text] [Related]
60. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
